Haitian Creole
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Polyphenol/Prebiotic Blend Effects on GI Health and Microbial Composition

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo
Log In / Enskri
Lyen an sove nan clipboard la
EstatiKonplete
Patwone
Pharmanex
Kolaboratè
KGK Science Inc.

Mo kle

Abstrè

The gastrointestinal (GI) ecosystem is a complex network of bacterial cells, host cells and tissues that change with age. Fewer numbers and less diversity of beneficial bacteria and greater number and diversity of non-beneficial bacteria occurs with age and conditions associated with accelerated aging (i.e. obesity, high fat diet)(1,2). This imbalance of the microbiota contributes to increased inflammation of the gastrointestinal lining and changes to the integrity of the intestinal cell wall.
Prebiotics, such as non-digestible carbohydrates, can induce the growth or activity microorganisms that contribute to the well-being of the host. Recent studies have shown that prebiotic treatment can have beneficial effects on glucose levels, lipid metabolism, and inflammatory markers in an obese population(3). The polyphenol blend is rich in anthocyanins, which is a unique subgroup of flavonoids that have been demonstrated to impact the microbiome and have anti-inflammatory properties(4,5,6,7). This open-label study will assess the benefits of a prebiotic and polyphenol blend in healthy obese adults.

Dat

Dènye verifye: 07/31/2016
Premye Soumèt: 04/10/2016
Enskripsyon Estimasyon Soumèt: 04/13/2016
Premye afiche: 04/18/2016
Dènye Mizajou Soumèt: 08/01/2016
Dènye Mizajou afiche: 08/02/2016
Dat aktyèl kòmanse etid la: 02/29/2016
Dat Estimasyon Prensipal Estimasyon an: 05/31/2016
Dat estime fini etid la: 05/31/2016

Kondisyon oswa maladi

GI Health
Microbial Composition

Entèvansyon / tretman

Dietary Supplement: Polyphenol/prebiotic blend

Faz

-

Gwoup bra

BraEntèvansyon / tretman
Other: Polyphenol/prebiotic blend
Nutritional Supplement. Active ingredients include: Inulin, Fructooligosaccharides, Polyphenol blend of anthocyanin sources--Blueberry extract, Black Currant extract, Black Rice extract. Participants will be instructed to consume one sachet of powder product every morning with breakfast by mixing into beverage or food of choice.
Dietary Supplement: Polyphenol/prebiotic blend

Kritè kalifikasyon yo

Laj ki kalifye pou etid 20 Years Pou 20 Years
Sèks ki kalifye pou etidAll
Aksepte Volontè HealthyWi
Kritè

Inclusion Criteria:

1. Males and Females 20-60 years of age

2. Female subjects of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include:

Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)

Double-barrier methods

Non-hormonal intrauterine devices

Vasectomy of partner

Non-heterosexual lifestyles

3. Subjects with BMI of 29.9-39.9±1 kg/m²

4. Subjects who agree to maintain their current level of physical activity throughout the trial period

5. Subjects who agree to discontinue the use or pre- and probiotic and/or polyphenol supplements from four weeks prior to baseline and for the duration of the study

6. Subjects who agree to discontinue foods containing anthocyanins (such as blueberries, blackberries, cherries, grapes, grape juice, pomegranate, raspberries, huckleberries, strawberries, and wine) from two weeks prior to baseline and for the duration of the study

7. Healthy as determined by laboratory results and medical history

8. Subjects must agree to comply with study procedures

9. Has given voluntary, written, informed consent to participate in the study

Exclusion Criteria:

1. Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial.

2. Subjects who have used an over-the-counter or prescription laxative medication within 4 weeks prior to baseline

3. Subjects who have used prebiotic, probiotic supplements or supplemented foods within 4 weeks of enrollment

4. Use of polyphenol supplements within 4 weeks prior to baseline

5. Subjects with type I diabetes or uncontrolled type II diabetes

6. Previous history of gastrointestinal surgery (except appendectomy, hernia repair, or hemorrhoidectomy).

7. Previous history of gastrointestinal diseases (except hemorrhoids and uncomplicated diverticula), as assessed by ultrasonography, colonoscopy, or rectoscopy, or history of Clostridium difficile-associated diarrhea

8. Presence of rectal bleeding (unless due to hemorrhoids)

9. Recent weight-loss (greater than 5 kg in the past month)

10. Iron deficiency (anemia) diagnosed within 3 months of baseline

11. Subjects who were smokers within 1 year of baseline

12. Subjects with active eating disorder

13. Subjects who have used oral antibiotics within 5 weeks of baseline

14. Unstable medical condition as determined by principal investigator

15. History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission more than 5 years of diagnosis are acceptable.

16. Alcohol abuse or drug abuse within the past 6 months

17. Consumption of >2 standard alcoholic drinks per day

18. Use of medicinal marijuana

19. Use of anti-inflammatory medications, more than once per week or if prescribed by a physician, 4 weeks prior to randomization and for the duration of the study

20. Participation in a clinical research trial within 30 days prior to baseline

21. Allergy or sensitivity to the test material's active or inactive ingredients

22. Allergy or sensitivity to Lactulose or Mannitol

23. Individuals who are cognitively impaired and/or who are unable to give informed consent

24. Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject

Rezilta

Mezi Rezilta Prensipal yo

1. Change from baseline in microbial composition in the feces at day 57 [Baseline, Day 57]

Mezi Rezilta Segondè

1. Change from baseline in calprotectin in the feces at day 57 [Baseline, Day 57]

2. Change from baseline in IL-6 in the feces at day 57 [Baseline, Day 57]

3. Change from baseline in IL-8 in the feces at day 57 [Baseline, Day 57]

4. Change from baseline in IL-10 in the feces at day 57 [Baseline, Day 57]

5. Change from baseline in IL-1β in the feces at day 57 [Baseline, Day 57]

6. Change from baseline in IL-12p70 in the feces at day 57 [Baseline, Day 57]

7. Change from baseline in TNFα in the feces at day 57 [Baseline, Day 57]

8. Change from baseline in urine sugar test for gut permeability at day 57 [Baseline, Day 57]

9. Change from baseline in plasma zonulin at day 57 [Baseline, Day 57]

10. Change from baseline in Total Cholesterol at day 57 [Baseline, Day 57]

11. Change from baseline in HDL-C at day 57 [Baseline, Day 57]

12. Change from baseline in LDL-C at day 57 [Baseline, Day 57]

13. Change from baseline in Triglycerides at day 57 [Baseline, Day 57]

14. Change from baseline in weekly mean of daily Bristol Stool Scale (BSS) scores at day 57 [Baseline, Day 57]

15. Change from baseline in plasma endotoxin at day 57 [Baseline, Day 57]

Lòt Mezi Rezilta

1. Change from baseline in hematology and clinical chemistry at day 57 [Baseline, Day 57]

Looking at number of participants with abnormal laboratory values related to treatment

2. Change from baseline in kidney and liver function at day 57 [Baseline, Day 57]

Looking at number of participants with abnormal laboratory values related to treatment

3. Change from baseline in electrolytes at day 57 [Baseline, Day 57]

4. Change from baseline in heart rate at day 57 [Baseline, Day 57]

5. Change from baseline in blood pressure at day 57 [Baseline, Day 57]

6. Change from baseline in adverse events at day 57 [Baseline, Day 57]

Antre nan paj
facebook nou an

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

  • Travay nan 55 lang
  • Geri èrbal te apiye nan syans
  • Remèd fèy rekonesans pa imaj
  • Kat entèaktif GPS - tag zèb sou kote (vini byento)
  • Li piblikasyon syantifik ki gen rapò ak rechèch ou an
  • Search remèd fèy medsin pa efè yo
  • Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye

Google Play badgeApp Store badge